LIPPINCOTT WILLIAMS AND WILKINS
|
|
- Gwenda May
- 6 years ago
- Views:
Transcription
1 AUTHOR QUERY FORM LIPPINCOTT WILLIAMS AND WILKINS JOURNAL NAME: MCG ARTICLE NO: jcg4488 QUERIES AND / OR REMARKS QUERY NO. Details Required Author s Response Q Q2 Q Q4 A running head short title was not supplied; please check if this one is suitable and, if not, please supply a short title of up to 0 characters that can be used instead. Ruhl et al has been changed to Ruhl and Everhart so that this citation matches the reference list. Please confirm that this is correct. Please confirm whether the change made in the sentence Furthermore, there was ayyy. is OK. As reference citations were not in order, we have rearranged them, please check.
2 CE: Sandhya ED: Prathiba Op: csr : LWWUS_MCG_jcg4488 PRESENTATION Coffee and Liver Health Filomena Morisco, MD, Vincenzo Lembo, PhD, Giovanna Mazzone, PhD, Silvia Camera, MD, and Nicola Caporaso, MD Abstract: Coffee is one of the most widely used beverages in the world. It includes a wide array of components that can have potential implications for health. Several epidemiological studies associate coffee consumption with a reduced incidence of various chronic diseases such as diabetes, cardiovascular diseases, and neurodegenerative diseases. Over the past 20 years, an increasing number of epidemiological and experimental studies have demonstrated the positive effects of coffee on chronic liver diseases. Coffee consumption has been inversely associated with the activity of liver enzymes in subjects at risk, including heavy drinkers. Coffee favours an improvement in hepatic steatosis and fibrosis, and a reduction in cirrhosis and the risk of hepatocellular carcinoma. The mechanisms of action through which it exerts its beneficial effects are not fully understood. Experimental studies show that coffee consumption reduces fat accumulation and collagen deposition in the liver and promotes antioxidant capacity through an increase in glutathione as well as modulation of the gene and protein expression of several inflammatory mediators. Animal and in vitro studies indicate that cafestol and kahweol, 2 diterpens, can operate by modulating multiple enzymes involved in the detoxification process of carcinogens causing hepatocellular carcinoma. It is unclear whether the benefits are significant enough to treat patients with chronic liver disease. While we await clarification, moderate daily unsweetened coffee use is a reasonable adjuvant to therapy for these patients. Key Words: coffee, NAFLD, cirrhosis, hepatocellular carcinoma (J Clin Gastroenterol 204;00: ) Coffee, appreciated for its aroma and flavor, is the most popular and common worldwide drink, and its frequent use derives principally from its invigorating characteristics and exciting properties. Coffee is a complex mixture of approximately 000 compounds and caffeine does not represent the main component. There are carbohydrates, lipids, proteins, minerals, potassium, and magnesium. Furthermore, coffee is a rich source of antioxidants and other bioactive compounds such as chlorogenic acid, melanoidins, and diterpenes, and has a wide array of physiological effects. 2, Coffee is sold as 2 types of mixtures, Arabica and Robusta, which differ because of their content of caffeine and chlorogenic acid. Because of its widespread use, coffee is considered a major contributor of redox-active phytochemicals in the diet. Coffee consumption has been associated with various health benefits and a reduced incidence of various chronic diseases such as diabetes, cardiovascular diseases, and From the Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. The authors declare that they have nothing to disclose. Reprints: Filomena Morisco, MD, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via S. Pansini, -80, Naples, Italy ( filomena.morisco@unina.it). Copyright r 204 by Lippincott Williams & Wilkins neurodegenerative diseases. 4 More recently, coffee has been demonstrated to be inversely associated with total and cause-specific mortality. Drinking coffee, about 4 to 6 cups per day, lowers the risk of death by 0% in men and % in women.,8 Over the past 20 years, an increasing number of epidemiological and experimental studies have demonstrated the positive effects of coffee on chronic liver diseases. The beneficial effects span positive effects on liver enzymes to improvements in liver steatosis and fibrosis, and a reduction in the risk of cirrhosis and hepatocellular carcinoma (HCC). 4 Several case-control, cross-sectional, and randomized studies have assessed the association between coffee consumption and liver disease (Table ). COFFEE AND LIVER ENZYMES Drinking coffee has been associated with a decrease in serum concentrations of liver enzymes: alanine aminotransferase, aspartate aminotransferase, and g- glutamyltransferase. 0, 8 It should be noted that this inverse relationship is particularly strong in heavy drinkers of alcohol, 4, HCV patients, 40 and HIV-HCV coinfected patients. Ruhl and Everhart 8 in a cross-sectional study, conducted in about 6000 adult Americans at high risk of liver damage, found that coffee and caffeine consumption reduces the risk of elevated aminotranferase levels, and the reduction is related to the amount of caffeine consumed. In one of the largest studies, including over 2,000 Japanese subjects, Tanaka et al reported that coffee consumption had an independent/inverse association with decreased g-glutamyltransferase activity in male alcohol drinkers. In a cohort study of >2000 Italian patients aged years or over, Casiglia et al 6 observed that alanine aminotransferase values were lower in those who drank Z cups of coffee per day. COFFEE AND VIRAL HEPATITIS Few studies have examined the effects of coffee consumption in patients with chronic hepatitis C (HCV)., Freedman et al 6 reported that regular coffee intake was associated with decreased rates of liver disease progression among HCV patients. Modi et al 8 documented that coffee consumption has a beneficial impact on the severity of liver fibrosis in patients with HCV infection. Cardin and colleagues demonstrated that coffee consumption, in patients with HCV, reduces oxidative DNA damage, increases apoptosis, leads to telomere elongation and DNA stabilization, and finally reduces procollagen III deposition.,42 No association was found between coffee consumption and severity of chronic hepatitis B. 20 J Clin Gastroenterol Volume 00, Number 00, AQ
3 Morisco et al J Clin Gastroenterol Volume 00, Number 00, 204 AQ TABLE. List of Some Studies Evaluating the Effect of Coffee on Liver Diseases References Design Country Patients (n) Comments Coffee and Viral Hepatitis Costentin et al Cross-sectional France 8 Coffee and caffeine consumption improve histologic activity Freedman et al 6 Retrospective cohort USA 66 Coffee reduces the progression of HCV-related liver disease Freedman et al Retrospective cohort USA 88 Coffee induces a better virological response to peginterferon plus ribavirin in HCV patients Modi et al 8 Retrospective cohort USA Coffee consumption is associated with less severe fibrosis in HCV patients Carrieri et al Prospective cohort France 06 Coffee intake reduces the side effects of pegylated interferon and ribavirin Ong et al 20 Cross-sectional China 0 Lack of association between fibrosis in HBV patients Coffee and NAFLD Anty et al Cross-sectional France Regular but not espresso coffee is protective against liver fibrosis in patients with NAFLD Birerdinc et al 22 Cross-sectional USA 82 Caffeine reduces the risk of NAFLD Catalano et al Case-control Italy 0 Coffee is inversely related to severity of NAFLD Gutie` rrez-grobe et al 24 Case-control Mexico 0 Coffee intake has protective effect in NAFLD patients Molloy et al Cross-sectional USA 06 Coffee reduces the risk of fibrosis in NASH patients Coffee and Cirrhosis Corrao et al 26 Case-control Italy 282 Coffee is protective against alcoholic cirrhosis Corrao et al Case-control Italy 2 Alcoholic cirrhosis can be prevented by coffee and not other caffeinated beverages Gallus et al 28 Case-control Italy 6 Inverse association between coffee and cirrhosis Tverdal and Skurtveit Retrospective cohort Norway,06 Inverse association between coffee and cirrhosis Klatsky et al 0 Retrospective cohort USA,80 Coffee consumption protects against cirrhosis, especially alcoholic cirrhosis Coffee and hepatocellular carcinoma La Vecchia et al Case-control Italy 20 There is no association between coffee and liver cancer Ohishi et al 2 Case-control Japan 868 Daily coffee consumption is associated with decreased risk for HCC Gallus et al 28 Case-control Italy 20 Inverse association between coffee and HCC incidence Hu et al Prospective cohort Finland 60, Dose-dependent inverse association with risk of HCC Leung et al 4 Case-control Hong Kong 4 Moderate coffee consumption reduces risk of HCC in HBV chronic carriers HBV indicates hepatitis B viral infection; HCC, hepatocellular carcinoma; HCV, hepatitis C viral infection; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis. COFFEE AND NONALCOHOLIC FATTY LIVER DISEASES (NAFLD) The beneficial effects of coffee on the liver seem to be independent of the etiology and have been observed also in patients with NAFLD.,22,24 Catalano et al, in a casecontrol study on patients with NAFLD, found that less fatty liver involvement is present in coffee versus noncoffee drinkers, concluding that coffee use is inversely associated with the degree of bright liver, along with insulin resistance and obesity. Molloy provides the first demonstration of a histopathologic correlation between fatty liver disease and estimated coffee intake. The results suggest that, in patients with nonalcoholic steatohepatitis (NASH), increased intake of coffee confers a significantly decreased risk of advanced fibrosis: an inverse relationship was found between coffee consumption and hepatic fibrosis (r =., P = 0.0). Furthermore, there was a significant difference between the amount of coffee consumption in patients with bland steatosis/not-nash (P = 0.00), NASH stage 0 to, and NASH stage 2 to 4 (P = 0.00). Moderate coffee consumption may be a benign adjuvant to the comprehensive management of patients with NASH. Regarding the mechanism by which coffee exerts its effects on steatosis and fibrosis, there is a quantity of convincing evidence that it is able to reduce the rate of fat and collagen deposition in the liver. In a rat model of fatty liver disease, we showed that animals fed with high-fat diet and decaffeinated coffee showed lower levels of hepatic fat and collagen, reduced liver oxidative stress, and improved liver inflammation and fibrosis.,44 In a recent study, our group demonstrated that decaffeinated coffee consumption is able to modulate the expression of endoplasmic reticulum and mitochondrial chaperones both under standard diet and high-fat diet conditions. Among proteins upregulated by coffee consumption, there seems to be a particularly significant induction of the chaperone glucose-related protein 8 (GRP8), a master regulator of endoplasmic reticulum homeostasis, belonging to the heat shock protein 0 (HSP0) family. Consistent with GRP8 induction, coffee increases the expression of mitochondrial HSP0, which plays a pivotal role in endogenous antitumour defense against different cancers through activation of both innate and adaptive immune systems. In addition, coffee induces the expression of another chaperone called DJ-, which plays a role in autophagy, and is also a redox-sensitive protein that scavenges reactive oxygen species by increasing glutathione synthesis. Finally, coffee induces the expression of antioxidant and stress sensor proteins, in particular peroxiredoxin (PRDX), which is able to catalyze the peroxide reduction of H 2 O 2, organic hydroperoxides, and peroxynitrite. The PRDX induction leads to inhibition of JNK activation, which has been involved in NASH pathogenesis r 204 Lippincott Williams & Wilkins
4 AQ J Clin Gastroenterol Volume 00, Number 00, 204 Coffee and Liver Health AQ4 COFFEE AND CIRRHOSIS Several case-control studies have shown an inverse association between coffee consumption and cirrhosis. 26, In particular, Corrao and colleagues identified a dose-dependent inverse relationship between caffeine intake and risk of cirrhosis. The odds ratios of cirrhosis development decreased from.0 (lifetime noncoffee drinkers) to 0.6 (0.0 to 0.0) in those with an intake of Z4 cups of coffee daily. In addition, the authors demonstrated that this effect was not due to caffeine but rather to other factors, which probably include different ingredients of coffee and lifestyle factors correlated with coffee consumption. In a further case-control study, Gallus et al 28 found an inverse relationship between duration of coffee consumption and cirrhosis. Further large cohort studies conducted in the United States indicate that coffee consumption reduces the risk of mortality from alcoholic cirrhosis, increased coffee consumption leads to a decrease in the relative risk of alcoholic cirrhosis, 0,46 and that coffee decreases the risk of chronic liver disease among patients at increased risk of liver disease. COFFEE AND HCC Coffee has been associated with a reduced risk of HCC. 4 In a recent meta-analysis of epidemiological studies to provide updated information on how coffee drinking affects HCC risk, Bravi and colleagues found that the risk of HCC is reduced by 40% for any coffee consumption versus no consumption. Coffee has been shown to affect liver enzymes and development of cirrhosis, and therefore could protect against liver carcinogenesis. 48 The coffee constituents, namely cafestol and kahweol, may play an important protective role in hepatocarcinogenesis.,0 In animal and cell culture models, these diterpenes reduce the toxicity of a variety of carcinogens. Furthermore, cafestol and kahweol induce phase II enzyme activity, enhance hepatic glutathione levels, 2, and decrease liver DNA adducts. 4 CONCLUSIONS On the basis of the available data, coffee consumption seems to exert a beneficial effect on patients with liver diseases or at risk of developing liver diseases. It is unclear whether any of these benefits are significant enough to treat patients with chronic liver disease and further cross-sectional, cohort, case-control, animal, and cell culture studies are warranted to further elucidate the biochemical basis for the potential beneficial effects of coffee on liver disease patients. In the interim, moderate daily unsweetened coffee use is a reasonable adjuvant to therapy for these patients. REFERENCES. Larsson SC. Coffee, tea, and cocoa and risk of stroke. Stroke. 204;: Spiller MA. The chemical components of coffee. Prog Clin Biol Res. 84;8:.. Gómez-Ruiz JA, Leake DS, Ames JM. In vitro antioxidant activity of coffee compounds and their metabolites. J Agric Food Chem. 200;: Higdon JV, Frei B. Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr. 2006;46:0.. Freedman ND, Park Y, Abnet CC, et al. Association of coffee drinking with total and cause-specific mortality. N Engl J Med. 202;66:8 04,. 6. Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Curr Opin Lipidol. 200;8:.. Qi H, Li S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson s disease. Geriatr Gerontol Int. 204;4: Greenland S. A meta-analysis of coffee, myocardial infarction, and coronary death. Epidemiology. ;4: Wu JN, Ho SC, Zhou C, et al. Coffee consumption and risk of coronary heart diseases: a meta-analysis of prospective cohort studies. Int J Cardiol. 200;: Sugiyama K, Kuriyama S, Akhter M, et al. Coffee consumption and mortality due to all causes, cardiovascular disease, and cancer in Japanese women. J Nutr. 200;40: Lopez-Garcia E, Van Dam RM, Li TY, et al. The relationship of coffee consumption with mortality. Ann Intern Med. 2008; 48: Tamakoshi A, Lin Y, Kawado M, et al. Effect of coffee consumption on all-cause and total cancer mortality: findings from the JACC study. Eur J Epidemiol. 20;26:28.. Andersen LF, Jacobs DR Jr, Carlsen MH, et al. Consumption of coffee is associated with reduced risk of death attributed to inflammatory and cardiovascular diseases in the Iowa Women s Health Study. Am J Clin Nutr. 2006;8: La Vecchia CL. Coffee, liver enzymes, cirrhosis and liver cancer. J Hepatol. 200;42: Costentin CE, Roudot-Thoraval F, Zafrani ES, et al. Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol. 20;4:. 6. Freedman ND, Everhart JE, Hoefs JC, et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. J Hepatol. 200;0:60.. Freedman ND, Curto TM, Lindsay KL, et al. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology. 20;40:. 8. Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. J Hepatol. 200;: Carrieri MP, Cohen J, Salmon-Ceron D, et al. Coffee consumption and reduced self-reported side effects in HIV- HCV co-infected patients during PEG-IFN and ribavirin treatment: results from ANRS CO HEPAVIH. J Hepatol. 202;6:. 20. Ong A, Wong VW, Wong GL, et al. The effect of caffeine and alcohol consumption on liver fibrosis a study of 0 Asian hepatitis B patients using transient elastography. Liver Int. 20;:0 0.. Anty R, Marjoux S, Marinè-Barjoan E, et al. Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol. 202;: Birerdinc A, Stepanova M, Younossi ZM. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 20;: Catalano D, Martines GF, Tonzuso A, et al. Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 200;: Gutie` rrez-grobe Y, Chàvez-Tapia N, Sa` nchez-valle V, et al. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Ann Hepatol. 202;:0.. Molloy JW, Calcagno CJ, Williams CD, et al. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 202;: Corrao G, Lepore AR, Torchio P, et al. The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. Eur J Epidemiol. 4;0: Corrao G, Zambon A, Bagnardi V, et al. Coffee, caffeine, and the risk of liver cirrhosis. Ann Epidemiol. 200;: Gallus S, Tavani A, Negri E, et al. Does coffee protect against liver cirrhosis? Ann Epidemiol. 2002;2: r 204 Lippincott Williams & Wilkins
5 Morisco et al J Clin Gastroenterol Volume 00, Number 00, 204. Tverdal A, Skurtveit S. Coffee intake and mortality from liver cirrhosis. Ann Epidemiol. 200;: Klatsky AL, Morton C, Udaltsova N, et al. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med. 2006;66:0.. La Vecchia C, Ferraroni M, Negri E, et al. Coffee consumption and digestive tract cancers. Cancer Res. 8;: Ohishi W, Fujwara S, Cologne JB, et al. Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2008;: Hu G, Tuomilehto J, Pukkala E, et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. J Hepatol. 2008;48: Leung WW, Ho SC, Chan HLY, et al. Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. J Epidemiol Community Health. 20;:6 8.. Arnesen E, Huseby NE, Brenn T, et al. The Tromso Heart Study: distribution of, and determinants for, gamma-glutamyltransferase in a free-living population. ScandJClinLabInvest. 86;46: Casiglia E, Spolaore P, Ginocchio G, et al. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol. ;:.. Honjo S, Kono S, Coleman MP, et al. Coffee consumption and serum aminotransferases in middle-aged Japanese men. J Clin Epidemiol. 200;4: Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 200;28: Tanaka K, Tokunaga S, Kono S, et al. Coffee consumption and decreased serum gamma-glutamyltransferase and aminotransferase activities among male alcohol drinkers. Int J Epidemiol. 8;: Macaluso FS, Maida M, Minissale MG, et al. Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int. 20;20:646.. Carrieri MP, Lions C, Sogni P, et al. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO HEPAVIH cohort study. JHepatol. 204;60: Cardin R, Piciocchi M, Martines D, et al. Effects of coffee consumption in chronic hepatitis C: a randomized controlled trial. Dig Liver Dis. 20;: 04.. Vitaglione P, Morisco F, Mazzone G, et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology. 200;2: Esposito F, Morisco F, Verde V, et al. Moderate coffee consumption increases plasma glutathione but not homocysteine in healthy subjects. Aliment Pharmacol Ther. 200;: 60.. Salomone F, Li Volti G, Vitaglione P, et al. Coffee enhances the expression of chaperones and antioxidant proteins in rats with nonalcoholic fatty liver disease. Transl Res. 20;:. 46. Klatsky AL, Armstrong MA, Friedman GD. Coffee, tea, and mortality. Ann Epidemiol. ;: 8.. Ruhl CE, Everhart JE. Coffee and teas consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology. 200;: Bravi F, Bosetti C, Tavani A, et al. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol. 20;: 4.. Muriel P, Arauz J. Coffee and liver diseases. Fitoterapia. 200;8: Cavin C, Holzhaeuser D, Scharf G, et al. Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem Toxicol. 2002;40:.. Huber WW, Rossmanith W, Grusch M, et al. Effects of coffee and its chemopreventive components kahweol and cafestol on cytochrome P0 and sulfotransferase in rat liver. Food Chem Toxicol. 2008;46: Huber WW, Teitel CH, Coles BF, et al. Potential chemoprotective effects of the coffee components kahweol and cafestol palmitates via modification of hepatic N-acetyltransferase and glutathione S-transferase activities. Environ Mol Mutagen. 2004;44:2 6.. Lam LKT, Sparnins VL, Wattenberg LW. Isolation and identification of kahweol and cafestol palmitate as active constituents of green coffee beans that enhance glutathione S-transferase activity in the mouse. Cancer Res. 82;42: Forrester LM, Neal GE, Judath DJ, et al. Evidence for involvement of multiple forms of cytochrome P-0 in aflatoxin B metabolism in human liver. Proc Natl Acad Sci USA. 0;8: r 204 Lippincott Williams & Wilkins
6 Author Reprints For Rapid Ordering go to: Order Author(s) Name Title of Article Tax $ Total $ REPRINTS ORDERED & PURCHASED UNDER THE AUTHOR REPRINTS PROGRAM MAY NOT BE USED FOR COMMERCIAL PURPOSES Payment Ship to Name Address Dept/Rm City State Zip Country Telephone Journal of Clinical Gastroenterology *Article # *Publication Mo/Yr *Fields may be left blank if order is placed before article number and publication month are assigned. Quantity of Reprints $ Reprint Pricing Shipping 0 copies = $6.00 Within the U.S. - Covers (Optional) $ 00 copies = $ $.00 up to the first 00 copies 200 copies = $4.00 and $.00 for each 00 copies = $.00 additional 00 Shipping Cost $ 400 copies = $.00 copies Reprint Color Cost $ 00 copies = $2.00 Plain Covers $08.00 for first 00 copies $8.00 each add l 00 copies Reprint Color ($0.00/00 reprints) Outside the U.S. - $0.00 up to the first 00 copies and $0.00 for each additional 00 copies Tax U.S. and Canadian residents add the appropriate tax or submit a tax exempt form. MC VISA Discover American Express Account # / / Exp. Date Name Address Dept/Rm City State Zip Country Telephone Signature Use this form to order reprints. Publication fees, including color separation charges and page charges will be billed separately, if applicable. Payment must be received before reprints can be shipped. Payment is accepted in the form of a check or credit card; purchase orders are accepted for orders billed to a U.S. address. Prices are subject to change without notice. For quantities over 00 copies contact our Healthcare Dept. For orders shipping in the US and Canada: call , fax your order to or it to Meredith.Doviak@wolte rskluwer.com. Outside the US: dial , fax your order to or it to Christopher.Bassett@w olterskluwer.com. MAIL your order to: Lippincott Williams & Wilkins Author Reprints Dept. W. Camden St. Baltimore, MD 20 FAX: For questions regarding reprints or publication fees, reprints@lww.com OR PHONE: For Rapid Ordering go to:
ORIGINAL ARTICLE Dose- and Gender-dependent Interactions between Coffee Consumption and Serum GGT Activity in Alcohol Consumers
Alcohol and Alcoholism Vol. 48, No. 3, pp. 303 307, 2013 Advance Access Publication 14 March 2013 doi: 10.1093/alcalc/agt017 ORIGINAL ARTICLE Dose- and Gender-dependent Interactions between Coffee Consumption
More informationCriteria for Dx of NASH NONALCOHOLIC STEATOHEPATITIS. Liver Ultrasound Report. Presenter Disclosure Information. Definition of NASH
1 1:45 pm NASH: Burgeoning Epidemic SPEAKER Sanjiv Chopra, MD, MACP Presenter Disclosure Information The following relationships exist related to this presentation: Sanjiv Chopra, MD, MACP: No financial
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Nonalcoholic Fatty Liver Disease: The Burgeoning Epidemic
NONALCOHOLIC STEATOHEPATITIS Sanjiv Chopra, M.D., MACP Professor of Medicine Faculty Dean for Continuing Education Harvard Medical School Senior Consultant in Hepatology Beth Israel Deaconess Medical Center
More informationCriteria for Dx of NASH NONALCOHOLIC STEATOHEPATITIS. Presenter Disclosure Information. Definition of NASH
9:45 10:30 am NASH: Burgeoning Epidemic SPEAKER Sanjiv Chopra, MD, MACP Presenter Disclosure Information The following relationships exist related to this presentation: Sanjiv Chopra, MD, MACP: No financial
More informationCoffee Intake and Mortality from Liver Cirrhosis
Coffee Intake and Mortality from Liver Cirrhosis AAGE TVERDAL, PHD, AND SVETLANA SKURTVEIT, PHD PURPOSE: The aim of the study was to evaluate the association between coffee consumption and mortality from
More informationAn association between coffee consumption and
Association of Coffee and Caffeine Consumption With Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Degree of Hepatic Fibrosis Jeffrey W. Molloy, 1 Christopher J. Calcagno, 2 Christopher D. Williams,
More informationBiopsies. macrovesicular steatosis (zone III) Criteria for Dx of NASH. Liver Ultrasound Report. Definition of NASH
Definition of NASH Nonalcoholic steatohepatitis (NASH) is the term used to describe the distinct clinical entity in which patients lack a history of significant alcohol consumption but have liver biopsy
More informationRisk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화
Risk Factors and Preventive Measures for Hepatocellular carcinoma (HCC) 울산의대울산대병원소화기내과박능화 Risk factors for HCC development (I) Environmental factors Infectious HBV HCV HDV Alimentary Alcohol Diet High
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationROUNDTABLE REPORT Looking after the liver: lifestyle, coffee and caffeine
Hosted by the Institute for Scientific Information on Coffee in association with the British Liver Trust. Contents 1 Overview 3 2 Introduction 4 3 The experts 5 4 Background 6 5 Coffee and liver disease
More informationCLINICAL LIVER, PANCREAS, AND BILIARY TRACT
GASTROENTEROLOGY 2005;128:24 32 CLINICAL LIVER, PANCREAS, AND BILIARY TRACT Coffee and Caffeine Consumption Reduce the Risk of Elevated Serum Alanine Aminotransferase Activity in the United States CONSTANCE
More informationUltrasound showing. Biopsies. Criteria for Dx of NASH. macrovesicular steatosis (zone III) Bright echogenic liver. Definition of NASH
Definition of NASH Nonalcoholic steatohepatitis (NASH) is the term used to describe the distinct clinical entity in which patients lack a history of significant alcohol consumption but have liver biopsy
More informationORIGINAL INVESTIGATION. Coffee, Cirrhosis, and Transaminase Enzymes
ORIGINAL INVESTIGATION Coffee, Cirrhosis, and Transaminase Enzymes Arthur L. Klatsky, MD; Cynthia Morton, MD; Natalia Udaltsova, PhD; Gary D. Friedman, MD Background: A minority of persons at risk develop
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationImproving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationJose D Sollano, MD Professor of Medicine University of Santo Tomas Manila, Philippines. University of Santo Tomas
Jose D Sollano, MD Professor of Medicine Manila, Philippines International Variation in Age-Standardized Liver Cancer Incidence Rates in Both Sexes, 2008 Global Age-Standardized Liver Cancer Incidence
More informationAssociation Of Caffeine Intake and Histological Features of Chronic Hepatitis C
Accepted Manuscript Association Of Caffeine Intake and Histological Features of Chronic Hepatitis C Charlotte E. Costentin, Françoise Roudot-Thoraval, Elie-Serge Zafrani, Fatiha Medkour, Jean-Michel Pawlotsky,
More informationEarly life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.
Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem
More informationCDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health
CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health Obesity and NAFLD Definitions: Nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver
More informationHealthy Liver Cirrhosis
Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The
More informationUMHS-PUHSC JOINT INSTITUTE
Role of Visceral Adiposity in the Pathogenesis of Non-Alcoholic Fatty Liver Disease in Lean versus Obese Patients: A Comparative Study between Patients at UMHS versus PUHSC Lai WEI and Anna LOK W Zhang,
More informationCoffee Consumption is Associated with a Lower Incidence of Fatty Liver in Middle-aged Men
406 Journal of Health Science, 57(5) 406 413 (2011) Research Letter Coffee Consumption is Associated with a Lower Incidence of Fatty Liver in Middle-aged Men Kazuo Funatsu, Takeshi Yamashita, and Haruo
More informationManagement of Liver Diseases: A Nonhepatologist s Viewpoint
Management of Liver Diseases: A Nonhepatologist s Viewpoint Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston,
More informationLiver Pathology in the 0bese
Liver Pathology in the 0bese Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Ludwig et al. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
More informationDietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and
Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic
More informationNational Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008
Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationEighty percent of hepatocellular carcinoma cases are caused by infection with hepatitis B virus
Chapter 1 Prevention Introduction Eighty percent of hepatocellular carcinoma cases are caused by infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). Cases of fatty liver and nonalcoholic
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationFatty liver disease: What do we know?
Fatty liver disease: What do we know? Prof. Dr. Claus Niederau Katholische Kliniken Oberhausen ggmbh St. Josef-Hospital Academic Teaching Hospital University of Duisburg-Essen NAFLD Non-Alcoholic Fatty
More informationCoffee consumption and risk of hepatocellular carcinoma: a meta-analysis of cohort studies
Page 1 of 10 Systematic Reviews Coffee consumption and risk of hepatocellular carcinoma: a meta-analysis of cohort studies J Li 1, M Xu 2, Z Cheng 3, P Wang 4, S Wei 1, X Ma 1, G Li 5 * Abstract Introduction
More informationNAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology
NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary
More informationIn Search of New Biomarkers for Nonalcoholic Fatty Liver Disease
REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationNON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES
NON-ALCOHOLIC STEATOHEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASES Preface Zobair M. Younossi xiii Epidemiology and Natural History of NAFLD and NASH 1 Janus P. Ong and Zobair M. Younossi Understanding
More informationNormal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos
Fatty liver disease Its not just for big boys anymore Ken Flora, MD, FAASLD, FACG, AGAF No disclosures Common situation Normal ALT for men 30 IU/L 36% US males abnormal Normal ALT for women 20 IU/L 28%
More informationDoes Viral Cure Prevent HCC Development
Does Viral Cure Prevent HCC Development Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute of Digestive Disease Director, Center for Liver Health Assistant Dean,
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationMETABOLIC SYNDROME AND HCV: FROM HCV
METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationFebruary 8, World Journal of Gastroenterology. Re: ESPS Manuscript No Dear Dr. Qi:
February 8, 2017 World Journal of Gastroenterology Re: ESPS Manuscript No. 32025 Dear Dr. Qi: My co-authors and I respectfully submit the accompanying revised manuscript, Early hepatitis B viral DNA clearance
More informationNON-ALCOHOLIC FATTY LIVER DISEASE:
NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology
More informationPEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE
PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationLiver disease is a major cause of mortality and morbidity
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9:524 530 Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008 ZOBAIR M. YOUNOSSI,*, MARIA
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationBio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis
AASLD 2015 /FibroSure Scientific Publications Section 1 - compared to APRI, FIB-4 and transient elastography Houot 2015, TE, FIB-4, APRI Meta-analysis is superior to TE by Fibroscan, APRI and Fib-4 using
More informationSteatosi epatica ed HCV
Steatosi epatica ed HCV Malattie delle vie biliari ed Epatologia Rho, Auditorium Padri Oblati, 11 Novembre 2006 Piero L. Almasio Università di Palermo HISTOPATHOLOGY Steatosis and accelerated fibrogenesis:
More informationHCC Prevention. Jee-Fu Huang. Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan. TCC, HCC Prevention, 26 Nov, 2011
HCC Prevention Jee-Fu Huang Kaohsiung Municipal Hsiao-Kang Hospital, KMUH Kaohsiung (Takao), Taiwan TCC, HCC Prevention, 26 Nov, 2011 1 Outline Pathogenic and Risk Factors HBV HCV Primary Secondary Primary
More informationWhat should I drink? Monica Esquivel ECHO Diabetes Learning Group December 6, 2017
What should I drink? Monica Esquivel ECHO Diabetes Learning Group December 6, 2017 Learning Objectives Describe relationship between added sugar and sugar sweetened beverages intake and health Differentiate
More informationAASLD Immune tolerant phase HBV NAFLD diagnostic HCC
AASLD 2016 Immune tolerant phase HBV NAFLD diagnostic HCC Immune tolerant 3 Modified from Chan HLY and Wong VWS. Hepatitis B. In Zakim and Boyers s Hepatology 2012 2015 AMERICAN ASSOCIATION FOR THE S1T6UDY
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationFirst European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health
First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st 2017 NAFLD/NASH : an expanding burden on liver health Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière,
More informationUniversity of Groningen. Non-alcoholic fatty liver disease Sheedfar, Fareeba
University of Groningen Non-alcoholic fatty liver disease Sheedfar, Fareeba IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationApproximately, 70% 80% of individuals exposed to
GASTROENTEROLOGY 2011;140:1961 1969 Coffee Consumption Is Associated With Response to Peginterferon and Ribavirin Therapy in Patients With Chronic Hepatitis C NEAL D. FREEDMAN,* TERESA M. CURTO, KAREN
More informationWORLDWIDE EPIDEMIOLOGY OF NASH
WORLDWIDE EPIDEMIOLOGY OF NASH Stefano Bellentani, M.D., Ph.D. Chief of Gastroenterology and Hepatology Service Clinica Santa Chiara Locarno Switzerland & Fondazione Italiana Fegato (FIF), Bassovizza (Trieste),
More informationCoffee consumption in relation to Type 2 Diabetes Mellitus. Haley Herbst Texas A&M University May 5, 2011
Coffee consumption in relation to Type 2 Diabetes Mellitus Haley Herbst Texas A&M University May 5, 2011 Coffee and Type 2 Diabetes 2 Abstract Scientific data has reported an inverse association in which
More informationLiver diseases: A major, neglected global public health problem requiring urgent actions and large- scale screening
Received: 19 December 2017 Accepted: 24 December 2017 DOI: 10.1111/liv.13682 REVIEW ARTICLE Liver diseases: A major, neglected global public health problem requiring urgent actions and large- scale screening
More informationNIH Public Access Author Manuscript Am J Med Sci. Author manuscript; available in PMC 2015 January 01.
NIH Public Access Author Manuscript Published in final edited form as: Am J Med Sci. 2014 January ; 347(1):. doi:10.1097/maj.0b013e31828b25a5. Association Between Metabolic Syndrome and Its Individual
More informationNonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse
Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse National Institute of Diabetes and Digestive and Kidney Diseases NATIONAL INSTITUTES OF HEALTH Nonalcoholic steatohepatitis
More informationDiabetes is a condition with a huge health impact in Asia. More than half of all
Interventions to Change Health Behaviors and Prevention Rob M. van Dam, PhD Diabetes is a condition with a huge health impact in Asia. More than half of all people with diabetes live today in Asian countries,
More informationNONALCOHOLIC FATTY LIVER DISEASE
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD, MSc Hepatology and Liver Transplantation University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Terminology Pathogenesis
More informationNon-Alcoholic Fatty Liver Diseasean underestimated epidemic
Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
More informationSTOP Hepatocellular Carcinoma
STOP Hepatocellular Carcinoma Laura Tenner MD MPH, Amit G. Singal MD MS, Mamta Jain MD, Barbara Turner MD, Barbara Riske MS ReACH Center and Dept of Medicine UT Health San Antonio Dept of Medicine UT Southwestern
More informationNONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat
More informationWhat is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob
Presenter Disclosure Information 5 6pm Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic SPEAKER Elliot Tapper, MD The following relationships exist related to this presentation:
More informationWhite Nights of Hepatology 2016
White Nights of Hepatology 2016 Saint Petersburg, 3 June 2016 Long-term treatment of Chronic hepatitis B - a key to HCC prevention Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationSpring 2017 Health & Wellness Seminar Series. Seminar 1: April 25 th, 2017
Spring 2017 Health & Wellness Seminar Series Seminar 1: April 25 th, 2017 1 Breakthroughs in Screening & Treatment of Liver Disease: From Hepatitis C and Fatty Liver Disease to Liver Cancer Robert S. Brown,
More informationDM, NAFLD, and conjugated linoleic acid (omega 6); what is the link
DM, NAFLD, and conjugated linoleic acid (omega 6); what is the link Mona Hegazy Professor of Internal Medicine Hepatology Department Cairo University Egypt Agenda Congugated lionleic fatty acid NAFLD
More informationNon-Alcoholic Fatty Liver Disease (NAFLD)
HEPATO-PANCREATO-BILIARY STOMACH CANCER PROGRAM Non-Alcoholic Fatty Liver Disease (NAFLD) Steatosis and Non-Alcoholic Steatohepatitis (NASH) Management Recommendations UCSF Fresno Department of Surgery
More information5/2/2016. Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, Massachusetts
Management of Liver Diseases (A Nonhepatologist s Viewpoint) Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, Massachusetts FINAL: 04/11/2016
More informationHepatocellular Carcinoma: Epidemiology and Screening
Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman
More informationSteatotic liver disease
Steatotic liver disease Fatty liver disease Prof. Dr. ANNE HOORENS Non-Neoplastic Liver Pathology December 8th 2018 Working Group of Digestive Pathology Belgian Society of Pathology OUTLINE NAFLD = Non-Alcoholic
More informationAccepted Manuscript. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming?
Accepted Manuscript Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming? Qing-Lei Zeng, Zhi-Qin Li, Hong-Xia Liang, Guang-Hua Xu, Chun-Xia
More informationM30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH
M30 Apoptosense ELISA A biomarker assay for detection and screening of NASH NASH A Global Disease In the Western countries, Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver disease, strongly
More informationCoffee is one of the most widely consumed beverages in the world.
A Newsletter for the Participants of the Multiethnic Cohort Study Multiethnic Cohort Update 24 Years of Epidemiological Research in Cancer Prevention The Multiethnic Cohort Study (MEC), which is being
More information6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare
6 Riunione Monotematica A.I.S.F. 2015 NASH malattia epatica, oncologica e cardiovascolare Modena, 9 ottobre 2015 Massimo Colombo NAFLD e HCC: caratteristiche distintive Chairman Department of Liver, Kidney,
More informationThe future s bright, the future s orange. the challenges of liver disease now and in the next 50 years
The future s bright, the future s orange. the challenges of liver disease now and in the next 50 years Peter Collins Consultant Hepatologist Bristol Royal Infirmary the challenges of liver disease now
More informationAlcohol's Effects on the Body
Alcohol's Effects on the Body Drinking too much on a single occasion or over time can take a serious toll on your health. Here s how alcohol can affect your body: Brain: Alcohol interferes with the brain
More informationLiver biopsy as the gold standard for diagnosis. Pierre BEDOSSA
Liver biopsy as the gold standard for diagnosis Pierre BEDOSSA 1 PATHOLOGY OF NAFLD CONFLICTS OF INTEREST Grants and funding from Genfit, Intercept, Allergan, Inventiva, OWL, Echosens CEO and funding of
More informationFatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London
Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London Fatty liver- how important is it? Importance in terms of: Prevalence Pathogenesis
More informationThe effect of aerobic exercise on serum level of liver enzymes and liver echogenicity in patients with non-alcoholic fatty liver disease
Gastroenterology and Hepatology From Bed to Bench. 2013 RIGLD, Research Institute for Gastroenterology and Liver Diseases ORIGINAL ARTICLE The effect of aerobic exercise on serum level of liver enzymes
More informationAlcol e tumori con focus sulle basse dosi
Alcol e tumori con focus sulle basse dosi Carlo La Vecchia Department of Epidemiology, Istituto Mario Negri Department of Clinical Sciences and Community Health, Università degli Studi di Milano 1 Cancers
More informationNAFLD/NASH in Sub- Saharan Africa
NAFLD/NASH in Sub- Saharan Africa Corné Kruger Gastroenterologist Durbanville Mediclinic Cape Town Liver Interest group meeting: Cape Town 2015 Introduction NAFLD is the most common liver disease disease
More informationAbstract and Introduction. Patients and Methods. M. Hedenstierna; A. Nangarhari; A. El-Sabini; O. Weiland; S.
www.medscape.com Cirrhosis, High Age and High Body Mass Index Are Risk Factors for Persisting Advanced Fibrosis After Sustained Virological Response in Chronic Hepatitis C M. Hedenstierna; A. Nangarhari;
More informationNash with cirrhosis icd 10
Free, official coding info for 2018 ICD-10-CM K75.81 - includes detailed crosswalks, DRG grouping and more. Free, official coding info for 2018 ICD-10-CM K74.69 - includes detailed crosswalks, DRG grouping
More informationWhat have we learned from HBV clinical cohorts?
PHC 2015: Hepatitis B What have we learned from HBV clinical cohorts? Jia-Horng Kao MD, Ph D Graduate Institute of Clinical Medicine, Hepatitis Research Center, Department of Internal Medicine, National
More informationPREVALENCE OF NAFLD & NASH
- - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)
More informationPHC, Paris, 30th Jan 2017 PATHOLOGY OF NAFLD. Pierre Bedossa. Departement of Pathology Hôpital Beaujon University Paris-Diderot Paris - FRANCE
PHC, Paris, 30th Jan 2017 PATHOLOGY OF NAFLD Pierre Bedossa Departement of Pathology Hôpital Beaujon University Paris-Diderot Paris - FRANCE 1 PATHOLOGY OF NAFLD NAFLD: a chronic liver disease with a wide
More informationAmerican Journal of Oral Medicine and Radiology
American Journal of Oral Medicine and Radiology e - ISSN - XXXX-XXXX ISSN - 2394-7721 Journal homepage: www.mcmed.us/journal/ajomr PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE AMONG TYPE 2 DIABETIC POPULATION
More informationLiver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals
Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer
More informationHealth Promotion by Antioxidants
Functional Foods in Health and Disease 2011,1(12):574-581 Page 574 of 581 Research Article Open Access Health Promotion by Antioxidants *Hoyoku Nishino 1,2, Michiaki Murakoshi 1,3, Yoshiko Satomi 4 1 KyotoPrefectural
More informationHIV coinfection and HCC
HIV coinfection and HCC 3 rd APASL STC on HCC 21 st -23 rd Nov 2013 Cebu, Phillippines George KK Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond) Consultant, Humanity and Health GI
More informationDisease Burden of Non Alcoholic Fatty Liver Disease (NAFLD)
Disease Burden of Non Alcoholic Fatty Liver Disease (NAFLD) Dr. H. Razavi May 31, 2017 First European NASH NAFLD Summit Disclosure: This work with funded by a multi-sponsored research grant from Intercept,
More information